Galderma raises guidance: what it means for Galderma stock

Published on 10/07/2026 at 10:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half net sales rose 24.60 percent in 2026. Galderma stock costs EUR 172.88 on October 7, 2026 after EUR 171.95, plus 0.54 percent.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma (CH1335392721) was trading at EUR 172.88 at Lang & Schwarz on October 7, 2026 at 10:39 a.m. CEST, up 0.54 percent versus the EUR 171.95 prior close. According to Galderma on September 21, 2026, the company raised its full-year 2026 net sales growth guidance to 19.00-21.00 percent at constant currency from 17.00-20.00 percent. The change gives Galderma stock a clear operating benchmark, even as the daily share-price move remains limited.

What the guidance means

Galderma's first-half 2026 net sales increased 24.60 percent year over year at constant currency, supporting the higher full-year range. The company also reaffirmed its Core EBITDA margin guidance at 26.00 percent for full-year 2026, according to Galderma.

The half-year earnings call supplied the operating detail behind that outlook. Yahoo Finance reported that first-half 2026 net sales reached USD 3.10 billion, while Core EBITDA rose 42.80 percent to USD 802.00 million and Core EBITDA margin reached 25.60 percent. Core net income rose 66.30 percent to USD 547.00 million.

Growth is broad but execution matters

The strongest quantified contribution came from Therapeutic Dermatology, where first-half 2026 net sales reached USD 848.00 million, up 67.90 percent at constant currency, with Nemluvio contributing USD 433.00 million. Injectable Aesthetics generated USD 1.40 billion, up 12.10 percent, while Dermatological Skincare reached USD 848.00 million, up 16.40 percent, according to Yahoo Finance.

For investors, the key tension is the gap between broad portfolio growth and product-specific execution. The same call described a U.S. FDA complete response letter for Relfydess and said the company was working toward a resubmission, while management maintained that the issue would not affect its midterm guidance through 2027. Nemluvio, by contrast, was expected to pass USD 1.00 billion in sales during 2026.

SMI membership adds visibility

Galderma began trading as a Swiss Market Index constituent on September 21, 2026, less than three years after its March 2024 initial public offering. The company reported that 2025 net sales reached USD 5.207 billion, compared with USD 4.410 billion in 2024, while first-half 2026 growth continued at 24.60 percent at constant currency.

Galderma stock stays near its market range

The Lang & Schwarz quote stood at EUR 172.88 on October 7, 2026 at 10:39 a.m. CEST, plus 0.54 percent against the EUR 171.95 prior close of October 6, 2026. Galderma's market capitalization was CHF 37.7 billion as of October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of Galderma stock.